This article has been cited by
1Hospitality co-creation with mobility-impaired people
Pearl M.C. Lin,Kang-Lin Peng,Lianping Ren,Chong-Wei Lin
International Journal of Hospitality Management.2019;77()492
[DOI]
2Adverse reactions to fluoroquinolones in the Nigerian population: an audit of reports submitted to the National Pharmacovigilance Centre from 2004 to 2016
Ibrahim A. Oreagba,Kazeem A. Oshikoya,Comfort Ogar,Abiodun O. Adefurin,Ali Ibrahim,Olufunsho Awodele,Yetunde Oni
Pharmacology Research & Perspectives.2017;5(2)e00297
[DOI]
3Adverse reactions to fluoroquinolones in the Nigerian population: an audit of reports submitted to the National Pharmacovigilance Centre from 2004 to 2016
Ramadan M. Elkalmi,Yaser Mohammed Al-Worafi,Wafa Mohammed Alseragi,Long Chiau Ming,Abubakar Siddique
Pharmacology Research & Perspectives.2020;5(2)245
[DOI]
4Knowledge, attitudes & practices of healthcare professionals in hospitals towards the reporting of adverse drug reactions in Saudi Arabia: A multi-centre cross sectional study
Thamir M. AlShammari,Mohammed J. Almoslem
Saudi Pharmaceutical Journal.2018;26(7)925
[DOI]
5Safety reporting through a comprehensive and pragmatic pharmcovigilance process for India and emerging markets: an industry perspective
Shashidhar Swamy,Meenakshi Mourya,Ganesh Kadhe,Amey Mane,Sandesh Sawant
Expert Opinion on Drug Safety.2015;14(9)1409
[DOI]
6A Survey on Pharmacovigilance Activities in ASEAN and Selected Non-ASEAN Countries, and the Use of Quantitative Signal Detection Algorithms
Cheng Leng Chan,Pei San Ang,Shu Chuen Li
Drug Safety.2017;40(6)517
[DOI]
7Pharmacovigilance in resource-limited countries
Sten Olsson,Shanthi N Pal,Alex Dodoo
Expert Review of Clinical Pharmacology.2015;8(4)449
[DOI]
8An overview of the pharmacovigilance system in India
Niti Mittal,Rakesh Mittal,M. C. Gupta
Clinical Research and Regulatory Affairs.2016;33(1)4
[DOI]
9An overview of the pharmacovigilance system in India
Shirley-Ann van der Spuy
Clinical Research and Regulatory Affairs.2017;33(1)161
[DOI]
10Post-marketing monitoring of intussusception after rotavirus vaccination in Japan
Vincent Bauchau,Lionel Van Holle,Olivia Mahaux,Katsiaryna Holl,Keiji Sugiyama,Hubert Buyse
Pharmacoepidemiology and Drug Safety.2015;24(7)765
[DOI]
11Post-marketing monitoring of intussusception after rotavirus vaccination in Japan
Yaser Mohammed Al-Worafi
Pharmacoepidemiology and Drug Safety.2020;24(7)279
[DOI]
12Comparative analysis of the use and control of thalidomide in Brazil and different countries: is it possible to say there is safety?
Soraya Machado de Jesus,Rafael Santos Santana,Silvana Nair Leite
Expert Opinion on Drug Safety.2021;24(7)1
[DOI]
13Potential Impact of Subsequent Entry Biologics in Nephrology Practice in Canada
Daniel J Martinusen,Clifford Lo,Judith G Marin,Nicole W Tsao,Marianna Leung
Canadian Journal of Kidney Health and Disease.2014;1(7)32
[DOI]
14Biosimilars in Rheumatic Diseases: Regulatory Guidelines, Efficacy and Safety Implications in Saudi Arabia
Hussein Halabi,Zeyad Al Zahrani,Ramiz Al Swailem,Waleed Husain,Hanan Al Rayes,Hanan Al Osaimi,Yasser El Dershaby,Haytham Mohamed Ahmed,Mohamed Mounir,Mohammed A. Omair
The Open Rheumatology Journal.2018;12(1)313
[DOI]
15Pharmacy students’ knowledge and perceptions about adverse drug reactions reporting and pharmacovigilance
Kingston Rajiah,Mari Kannan Maharajan,Shashina Nair
Saudi Pharmaceutical Journal.2016;24(5)600
[DOI]
16Respiratory concerns of gabapentin and pregabalin: What does it mean to the pharmacovigilance systems in developing countries?
Sunil Shrestha,Subish Palaian
F1000Research.2020;9(5)32
[DOI]
17Pharmacovigilance in China: development and challenges
Ying Zhao,Tiansheng Wang,Guangyao Li,Shusen Sun
International Journal of Clinical Pharmacy.2018;40(4)823
[DOI]
18Pharmacovigilance in China: development and challenges
Thomas Felix,Binakumari Patel,Brian D. Bradbury,Gustavo Grampp
International Journal of Clinical Pharmacy.2018;34(4)631
[DOI]
19Barriers to adverse drug reaction reporting in Malaysia: a narrative review based on theoretical domains framework
Shakirin Shaik Rahmat,Mahmathi Karuppannan
Journal of Pharmaceutical Health Services Research.2021;34(4)631
[DOI]
20Adverse Drug Reaction Reporting Pattern in Turkey: Analysis of the National Database in the Context of the First Pharmacovigilance Legislation
Gulnihal Ozcan,Emel Aykac,Yelda Kasap,Nergiz T. Nemutlu,Ebru Sen,N. Demet Aydinkarahaliloglu
Drugs - Real World Outcomes.2016;3(1)33
[DOI]
21Adverse Drug Reaction Reporting Pattern in Turkey: Analysis of the National Database in the Context of the First Pharmacovigilance Legislation
Maike Scherf-Clavel
Drugs - Real World Outcomes.2020;3(1)1
[DOI]
22Current status of pharmacovigilance regulatory structures, processes, and outcomes in the Asia-Pacific region: Survey results from 15 countries
Ju-Young Shin,Eungyeong Shin,Han Eol Jeong,Ju Hwan Kim,Eui-Kyung Lee
Pharmacoepidemiology and Drug Safety.2019;28(3)362
[DOI]
23Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting
Siew C Ng,Ida Normiha Hilmi,Aimee Blake,Fatima Bhayat,Shashi Adsul,Qasim Rana Khan,Deng-Chyang Wu
Inflammatory Bowel Diseases.2018;24(11)2431
[DOI]
24Medication Errors in the Southeast Asian Countries: A Systematic Review
Shahrzad Salmasi,Tahir Mehmood Khan,Yet Hoi Hong,Long Chiau Ming,Tin Wui Wong,Jong-Ling Fuh
PLOS ONE.2015;10(9)e0136545
[DOI]
25Respiratory concerns of gabapentin and pregabalin: What does it mean to the pharmacovigilance systems in developing countries?
Sunil Shrestha,Subish Palaian
F1000Research.2021;9(9)32
[DOI]
26Legislation and current developments in adverse drug reaction reporting in Mongolia: how far are we?
Zuzaan Zulzaga,Erdenetuya Myagmarsuren,Herman J. Woerdenbag,Eugene P. van Puijenbroek
Journal of Pharmaceutical Policy and Practice.2021;14(1)32
[DOI]
27Post-Marketing Benefit–Risk Assessment of Rotavirus Vaccination in Japan: A Simulation and Modelling Analysis
Edouard Ledent,Alfons Lieftucht,Hubert Buyse,Keiji Sugiyama,Michael Mckenna,Katsiaryna Holl
Drug Safety.2016;39(3)219
[DOI]
28A Cross-Sectional Pilot Study on Pharmacovigilance to Improve the Drug Safety in Bangladesh
Md. Akter Hossain,Md. Shah Amran
Biomedical & Pharmacology Journal.2019;12(3)1039
[DOI]
29A Cross-Sectional Pilot Study on Pharmacovigilance to Improve the Drug Safety in Bangladesh
Rabia Hussain,Mohamed Azmi Hassali,Zaheer-Ud-Din Babar
Biomedical & Pharmacology Journal.2020;12(3)1
[DOI]
30Anti-tumor necrosis factor biosimilars and intended copies in rheumatology: Perspective from the Asia Pacific region
Prasan Deep Rath,Der-Yuan Chen,Jieruo Gu,Vivian W. Y. Lee,Nizar Abdulateef Al Ani,Khalid Shirazy,Lyndon Llamado
International Journal of Rheumatic Diseases.2019;22(1)9
[DOI]
31Pharmacovigilance activities in ASEAN countries
Wimon Suwankesawong,Teerapon Dhippayom,Wei-Chuen Tan-Koi,Chuenjid Kongkaew
Pharmacoepidemiology and Drug Safety.2016;25(9)1061
[DOI]
  Feedback 
  Subscribe